
|Articles|October 1, 2016
- Pharmaceutical Executive-10-01-2016
- Volume 36
- Issue 10
Pharmaceutical Executive, October 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive October 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 9 years ago
Content Marketing’s Data Fail: Information Without Insight?about 9 years ago
The Rise of the CFO Strategist: Balancing Numbers and Know-howabout 9 years ago
Steps Toward Rare Disease Successover 9 years ago
‘Huge Sellers’ Herald Changes in Japan Drug Pricingover 9 years ago
Real-World Evidence: From Volume to Valueover 9 years ago
Pharma and the Peril of Europe’s Trade Policiesover 9 years ago
New Challenge to IP Innovationover 9 years ago
Major Changes Ahead for Drug User Feesover 9 years ago
Country Report: Czech RepublicNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
J.P. Morgan 2026: Pfizer’s Pivot from Covid to Pipeline Execution
2
Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment
3
Communicating Credibility and Timelines to Public-Market Investors at the 2026 J.P. Morgan Healthcare Conference
4
How Are Sites Impacted by Poor Planning and Trial Design?
5




